$164 Million is the total value of Birchview Capital, LP's 0 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AXDX | ACCELERATE DIAGNOSTICS INC | $49,965,000 | +8.8% | 2,183,795 | 0.0% | 30.39% | +5.7% | |
| ARRY | ARRAY BIOPHARMA INC | $7,783,000 | +90.0% | 168,000 | 0.0% | 4.73% | +84.5% | |
| NBIX | NEUROCRINE BIOSCIENCES INC | $4,644,000 | -4.2% | 55,000 | 0.0% | 2.82% | -7.0% | |
| EQM | EQM MIDSTRM PRTNERS LP LTDunit ltd partn | $2,234,000 | -3.2% | 50,000 | 0.0% | 1.36% | -6.1% | |
| HROW | HARROW HEALTH INC | $1,566,000 | +74.8% | 180,000 | 0.0% | 0.95% | +69.7% | |
| ARNA | ARENA PHARMACEUTICALS INC | $1,290,000 | +30.8% | 22,000 | 0.0% | 0.78% | +27.0% | |
| ALBO | ALBIREO PHARMA INC | $1,225,000 | +0.1% | 38,000 | 0.0% | 0.74% | -2.9% | |
| MASI | MASIMO CORP | $1,191,000 | +7.7% | 8,000 | 0.0% | 0.72% | +4.5% | |
| AMRN | AMARIN CORP PLCspons adr new | $1,144,000 | -6.6% | 59,000 | 0.0% | 0.70% | -9.4% | |
| VNDA | VANDA PHARMACEUTICALS INC | $1,127,000 | -23.4% | 80,000 | 0.0% | 0.68% | -25.7% | |
| T107PS | WRIGHT MEDICAL GROUP NV | $895,000 | -5.2% | 30,000 | 0.0% | 0.54% | -8.0% | |
| VYGR | VOYAGER THERAPEUTICS INC | $817,000 | +42.3% | 30,000 | 0.0% | 0.50% | +38.1% | |
| XLRN | ACCELERON PHARMA INC | $767,000 | -11.8% | 18,672 | 0.0% | 0.47% | -14.5% | |
| ODT | ODONATE THERAPEUTICS INC | $734,000 | +66.1% | 20,000 | 0.0% | 0.45% | +61.0% | |
| DRNA | DICERNA PHARMACEUTICALS INC | $709,000 | +7.6% | 45,000 | 0.0% | 0.43% | +4.4% | |
| DOVA | DOVA PHARMACEUTICALS INC | $705,000 | +58.4% | 50,000 | 0.0% | 0.43% | +53.8% | |
| SLNO | SOLENO THERAPEUTICS INC | $674,000 | +35.9% | 240,598 | 0.0% | 0.41% | +31.8% | |
| ICPT | INTERCEPT PHARMACEUTICALS INC | $660,000 | -28.9% | 8,300 | 0.0% | 0.40% | -31.0% | |
| ARVN | ARVINAS INC | $660,000 | +49.0% | 30,000 | 0.0% | 0.40% | +44.2% | |
| PXD | PIONEER NATURAL RESOURCES CO | $585,000 | +1.0% | 3,800 | 0.0% | 0.36% | -1.9% | |
| CORT | CORCEPT THERAPEUTICS INC | $558,000 | -4.9% | 50,000 | 0.0% | 0.34% | -7.9% | |
| MYGN | MYRIAD GENETICS INC | $556,000 | -16.3% | 20,000 | 0.0% | 0.34% | -18.8% | |
| XNCR | XENCOR INC | $503,000 | +31.7% | 12,300 | 0.0% | 0.31% | +28.0% | |
| LXRX | LEXICON PHARMACEUTICALS INC | $503,000 | +13.0% | 80,000 | 0.0% | 0.31% | +9.7% | |
| FOLD | AMICUS THERAPEUTICS INC | $474,000 | -8.3% | 38,000 | 0.0% | 0.29% | -11.1% | |
| KPTI | KARYOPHARM THERAPEUTICS INC | $419,000 | +2.4% | 70,000 | 0.0% | 0.26% | -0.4% | |
| NKTR | NEKTAR THERAPEUTICS | $338,000 | +6.0% | 9,500 | 0.0% | 0.21% | +3.0% | |
| CLR | CONTINENTAL RESOURCES INC | $337,000 | -5.9% | 8,000 | 0.0% | 0.20% | -8.5% | |
| SIEN | SIENTRA INC | $246,000 | -28.3% | 40,000 | 0.0% | 0.15% | -30.2% | |
| ECA | ENCANA CORP | $244,000 | -29.1% | 47,500 | 0.0% | 0.15% | -31.5% | |
| EQT | EQT CORPORATION | $179,000 | -23.5% | 11,300 | 0.0% | 0.11% | -25.9% | |
| TGTX | TG THERAPEUTICS INC | $130,000 | +7.4% | 15,000 | 0.0% | 0.08% | +3.9% | |
| CFRX | CONTRAFECT CORP | $123,000 | +28.1% | 240,203 | 0.0% | 0.08% | +25.0% | |
| YTEN | YIELD10 BIOSCIENCE INC | $120,000 | -14.9% | 123,639 | 0.0% | 0.07% | -17.0% | |
| CYTK | CYTOKINETICS INC | $113,000 | +39.5% | 10,000 | 0.0% | 0.07% | +35.3% | |
| XBIT | XBIOTECH INC | $76,000 | -30.9% | 10,000 | 0.0% | 0.05% | -33.3% | |
| WKHS | WORKHORSE GROUP INC | $74,000 | +393.3% | 25,000 | 0.0% | 0.04% | +400.0% | |
| LTHM | LIVENT CORP | $69,000 | -43.9% | 10,000 | 0.0% | 0.04% | -45.5% | |
| GNMX | AEVI GENOMIC MEDICINE INC | $20,000 | -20.0% | 128,000 | 0.0% | 0.01% | -25.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-06
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACCELERATE DIAGNOSTICS INC | 36 | Q3 2023 | 34.6% |
| QUIDELORTHO CORP | 36 | Q3 2023 | 8.6% |
| MASIMO CORP | 36 | Q3 2023 | 2.2% |
| PIONEER NATURAL RESOURCES CO (PXD) | 36 | Q3 2023 | 0.7% |
| XENCOR INC | 35 | Q3 2023 | 0.4% |
| NEUROCRINE BIOSCIENCES INC | 33 | Q3 2023 | 7.4% |
| CORCEPT THERAPEUTICS INC | 32 | Q3 2023 | 1.2% |
| BIOGEN INC | 31 | Q2 2022 | 3.1% |
| CONTRAFECT CORP | 30 | Q3 2022 | 1.6% |
| YIELD10 BIOSCIENCE INC | 26 | Q3 2023 | 0.6% |
View Birchview Capital, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SOLENO THERAPEUTICS INC | March 19, 2019 | 742,635 | 2.3% |
| YIELD10 BIOSCIENCE, INC. | December 29, 2017 | 186,079 | 2.2% |
| HANSEN MEDICAL INC | February 16, 2016 | ? | ? |
| METABOLIX, INC. | June 23, 2015 | 749,696 | 2.8% |
View Birchview Capital, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-14 |
| 3/A | 2024-02-20 |
| 4/A | 2024-02-20 |
| SC 13G/A | 2024-02-20 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-04-07 |
| 4 | 2023-03-27 |
View Birchview Capital, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.